Dr. Cochrane’s career has spanned the fields of medicine, biomedical research, education and business. He was the founding Dean of Medicine for the University of Calgary building a medical school from the ground up, instituting a new integrated and interdisciplinary approach to medical education that has since become the norm across Canada. In 1978, Dr. Cochrane took his career in a new direction as Chairman and Chief Executive Officer of Connaught Laboratories. During his tenure with the company, Connaught became a major international developer of flu vaccines for the World Health Organization. The company's developments, including insulin, plasma products and vaccines, served to improve the quality of life of people across Canada and around the world.

During his career, Dr. Cochrane has shared his leadership with a range of organizations, from the National Biotechnology Advisory Committee, the Alberta Research Council to private sector ventures and non-profit organizations. Dr. Cochrane was named an Officer of the Order of Canada in 1989. He holds many other honors, including a National Merit Award for his contribution to biotechnology in Canada, ASTech Foundation and BioAlberta. In 2005, the Alberta Medical Association named Dr. Cochrane one of Alberta's "Physicians of the Century."

Wayne Chiu is the Founder and President of Trico Developments Corporation and Trico Homes Inc., established in Calgary in 1989 and 1993 respectively. Over the past decade, Trico Homes has built over 5,000 quality single and multi-family homes in the Calgary area. Mr. Chiu is a Mechanical Engineering graduate from the University of Manitoba and a qualified master builder, serves as a Director of the Professional Home Builders’ Institute, and he is a member of the Institute of Corporate Directors. Wayne's numerous awards include, The City of Calgary Achievement Award 2008, Volunteer Calgary Leaders in Business Award 2007, Alberta Centennial Medal 2005, Immigrant of Distinction Business Award 2004 and Generosity Spirit Award 2004. Wayne is also a major supporter of the Kids Cancer Care Foundation, Calgary Chinese Community Services Association, Asian Heritage Month, and Mount Royal College, to name a few.

Jan Gray, CA is a practicing chartered accountant who specializes in advising high net worth individuals with complex financial, investment and taxation issues. She is also Executive Vice- President and Treasurer of Cartwright Canada Inc., a legal publishing company and Controller of Felesky Flynn LLP, a regional Alberta law firm.

Jan’s prior experience includes being a former Vice President and Controller of GE Capital Canada and previous to this she worked for Ernst & Young where she was a Manager in the National Accounting Group providing quality assurance on large public practice engagements.

Jan currently serves on the board of directors for the Auxilium Foundation where she administers the multi-million dollar charitable fund. In addition she is a regular volunteer with Inn From the Cold, Calgary’s only shelter for homeless families which allows the family to remain together.

Mr. Higgins started his career in 1978 in England with Bristol-Myers. He subsequently worked for Sandoz (1979 to 1984) and Fisons (1984 to 1987) before moving to Abbott Laboratories in the USA (1987 to 2001), where he held various positions of increasing responsibility in the international and domestic divisions, including a two-year posting in Germany. He was appointed President of the Pharmaceutical Products Division in Chicago, Illinois, USA, in 1998. In this position, he was in charge of Abbott's pharmaceuticals business in the United States with responsibility for global pharmaceutical research and development. In 2001, he was appointed Chairman and CEO of Enzon Pharmaceuticals headquartered in Bridgewater, New Jersey, USA. In this function, he also served as Chairman of the Biotech Council of New Jersey and on the board of the U.S. National Pharmaceutical Council.

Mr. Higgins represents Bayer in the Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), and is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). From May 2007 until December 2009, Mr. Higgins was President of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Donald McCaffrey is Co-Founder, President, & CEO of Resverlogix Corp. He has almost 30 years experience in drug discovery & development, and international conference and tradeshow management across multiple industries, including biotechnology. Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed company, including raising over CAD $140 million.  In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Don has strategically directed the Company in its discussions with top global pharmaceutical companies, while creating new therapeutic markets for its key technology platforms. Don’s expertise in corporate operations has attracted an international team of R&D experts to Resverlogix.  This scientific and operational expertise has pioneered RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease.  Under his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award.

Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Alberta Children's Hospital, Education Matters, and Calgary Urban Project Society Literacy Program.

Kelly is currently the Executive Vice President, Finance and Administration and Chief Financial Officer of IMRIS, a global leader in providing fully integrated, advanced surgical imaging solutions. Prior to joining IMRIS, Kelly was part of Resverlogix's Senior Management Team, where he made significant contributions as Chief Financial Officer.  Prior to Resverlogix, Kelly was General Manager at Haworth Ltd., a global office interiors manufacturer located in Calgary, Alberta. Haworth Ltd. is a subsidiary of Haworth Inc., a multinational office interiors manufacturer with nearly 9000 employees worldwide.  Kelly was previously Vice President, Finance at SMED International, a global office interiors manufacturer where he was part of a team that successfully defended a hostile takeover bid resulting in the sale to Haworth Inc. at a 74% premium over the share price prior to the unsolicited offer in December 1999. During his tenure at SMED International he was part of a team that raised $40 Million in equity financing in a secondary public offering on the TSX and NASDAQ. Kelly is a chartered accountant and earned a B.Comm (Hons), and M.Acc from the University of Manitoba.

Past board positions include Canada Foundation for Innovation, Enmax, Laidlaw Inc., Allstate Insurance Company of Canada, the Prime Minister's National Advisory Board on Science and Technology and the Alberta Research Council to name a few.

Stella has a B.A. in Economics from the University of Calgary and an M.A. in Economics from the University of Alberta.  In 2005, she was recognized by the Women’s Executive Network and the University Of Western Ontario’s Richard Ivey School of Business as one of Canada’s Top 100 Most Powerful Women.